Multi-omics of chronic obstructive pulmonary disease: from genetic and metabolomic disorders to personalized medicine
https://doi.org/10.21886/2712-8156-2025-6-4-28-42
Abstract
This review is devoted to the modern understanding of the genetic and metabolomic basis of development, features of the course and therapy of chronic obstructive pulmonary disease, one of the leading causes of morbidity and mortality in the world. It analyzes candidate disease genes, results of genome-wide association studies, and metabolomic changes in COPD. It describes methods for metabolomic profiling and integrative approaches to using this data in the diagnosis and treatment of COPD.
About the Authors
L. Y. Nikitina
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Lidiya Yu. Nikitina, Dr. Sci. (Med.), Associate Professor, Methodologist at the Department of Personnel Policy Analysis and Monitoring of Medical Care at the National Medical Research Center for Pulmonology
Moscow
S. V. Buikin
Yaroslav the Wise Novgorod State University
Russian Federation
Russian Federation
Stepan V. Buikin, Cand. Sci. (Med.), Associate Professor of the Department of Internal Diseases of the Medical Institute
Veliky Novgorod
V. R. Weber
Yaroslav the Wise Novgorod State University
Russian Federation
Russian Federation
Viktor R. Weber, Dr. Sci. (Med.), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Internal Diseases, Scientific Director of the Medical Institute
Veliky Novgorod
M. Z. Gasanov
Yaroslav the Wise Novgorod State University
Russian Federation
Russian Federation
Mithat Z. Hasanov, Cand. Sci. (Med.), Associate Professor, Associate Professor of the Department of Hospital Therapy, Deputy Director of the Medical Institute
Veliky Novgorod
S. N. Avdeev
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Sergey N. Avdeev, Dr. Sci. (Med.), Professor, acad. RAS, Head of the Department of Pulmonology, Director of the Clinic of Pulmonology and Respiratory Medicine, Director of the National Medical Research Center for Pulmonology
Moscow
References
1. Werder RB, Zhou X, Cho MH, Wilson AA. Breathing new life into the study of COPD with genes identified from genome-wide association studies. Eur Respir Rev. 2024;33(172):240019. doi: 10.1183/16000617.0019-2024
2. Cho MH, Hobbs BD, Silverman EK. Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder. Lancet Respir Med. 2022;10(5):485-496. doi: 10.1016/S2213-2600(21)00510-5
3. Buikin S.V., Puzyrev V.P. Alpha1 antitrypsin deficiency. prospect screening. the first report. Byulleten' Sibirskogo otdeleniya Rossiyskoy akademii meditsinskikh nauk = Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences. 2004;(1):92–98 (In Russ.). eLIBRARY ID: 9126426 EDN: HRSOHV
4. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5(3):e1000421. doi: 10.1371/journal.pgen.1000421
5. Ogorodova LM, Puzyryov VP, eds. Genetika bronkholegochnykh zabolevanii. Moscow: Atmosfera. 2010 (In Russ.)
6. Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, et al. Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020;201(5):564-574. doi: 10.1164/rccm.201905-1017OC
7. Pillai SG, Kong X, Edwards LD, Cho MH, Anderson WH, Coxson HO, et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(12):1498-1505. doi: 10.1164/rccm.201002-0151OC
8. Yuan C, Chang D, Lu G, Deng X. Genetic polymorphism and chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1385-1393. doi: 10.2147/COPD.S134161
9. Wang S, Yue Y, Wang X, Tan Y, Zhang Q. SCARF2 is a target for chronic obstructive pulmonary disease: Evidence from multi-omics research and cohort validation. Aging Cell. 2024;23(10):e14266. doi: 10.1111/acel.14266
10. Yang Q, Huang W, Yin D, Zhang L, Gao Y, Tong J, et al. EPHX1 and GSTP1 polymorphisms are associated with COPD risk: a systematic review and meta-analysis. Front Genet. 2023;14:1128985. doi: 10.3389/fgene.2023.1128985
11. Gilowska I, Majorczyk E, Kasper Ł, Bogacz K, Szczegielniak J, Kasper M, et al. The role of MMP-12 gene polymorphism - 82 A-to-G (rs2276109) in immunopathology of COPD in polish patients: a case control study. BMC Med Genet. 2019;20(1):19. doi: 10.1186/s12881-019-0751-9
12. Kam MLW, Chong ST, Chan SH, Swigris JJ, Chew EL, Tan YH, et al. First ever characterisation of the effects of short telomeres in a Singapore interstitial lung disease cohort. Respir Investig. 2024;62(3):348-355. doi: 10.1016/j.resinv.2024.02.004
13. Maremanda KP, Sundar IK, Li D, Rahman I. Age-Dependent Assessment of Genes Involved in Cellular Senescence, Telomere, and Mitochondrial Pathways in Human Lung Tissue of Smokers, COPD, and IPF: Associations With SARS-CoV-2 COVID-19 ACE2-TMPRSS2-Furin-DPP4 Axis. Front Pharmacol. 2020;11:584637. doi: 10.3389/fphar.2020.584637
14. Zhu Y, Meng Y, Zhang Y, Karlsson IK, Hägg S, Zhan Y. Genetically determined telomere length and its association with chronic obstructive pulmonary disease and interstitial lung disease in biobank Japan: A Mendelian randomization study. Heliyon. 2023;10(1):e23415. doi: 10.1016/j.heliyon.2023.e23415
15. Córdoba-Lanús E, Montuenga LM, Domínguez-de-Barros A, Oliva A, Mayato D, Remírez-Sanz A, et al. Oxidative Damage and Telomere Length as Markers of Lung Cancer Development among Chronic Obstructive Pulmonary Disease (COPD) Smokers. Antioxidants (Basel). 2024;13(2):156. doi: 10.3390/antiox13020156
16. Córdoba-Lanús E, Cazorla-Rivero S, García-Bello MA, Mayato D, Gonzalvo F, Ayra-Plasencia J, et al. Telomere length dynamics over 10-years and related outcomes in patients with COPD. Respir Res. 2021;22(1):56. doi: 10.1186/s12931-021-01616-z
17. Tacheva T, Zienolddiny-Narui S, Dimov D, Vlaykova D, Miteva I, Vlaykova T. The Leucocyte Telomere Length, GSTM1 and GSTT1 Null Genotypes and the Risk of Chronic Obstructive Pulmonary Disease. Curr Issues Mol Biol. 2022;44(8):3757-3769. doi: 10.3390/cimb44080257
18. Ruiz A, Flores-Gonzalez J, Buendia-Roldan I, Chavez-Galan L. Telomere Shortening and Its Association with Cell Dysfunction in Lung Diseases. Int J Mol Sci. 2021;23(1):425. doi: 10.3390/ijms23010425
19. Cagsin H, Uzan A, Tosun O, Rasmussen F, Serakinci N. Tissue-Specific Ultra-Short Telomeres in Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis. 2020;15:2751-2757. doi: 10.2147/COPD.S267799
20. Bowler RP, Jacobson S, Cruickshank C, Hughes GJ, Siska C, Ory DS, et al. Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med. 2015;191(3):275-284. doi: 10.1164/rccm.201410-1771OC
21. Ubhi BK, Cheng KK, Dong J, Janowitz T, Jodrell D, Tal-Singer R, et al. Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD. Mol Biosyst. 2012;8(12):3125-3133. doi: 10.1039/c2mb25194a
22. Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:3341-3348. doi: 10.2147/COPD.S176122
23. Kanto N, Ohkawa Y, Kitano M, Maeda K, Shiida M, Ono T, et al. A highly specific antibody against the core fucose of the N-glycan in IgG identifies the pulmonary diseases and its regulation by CCL2. J Biol Chem. 2023;299(12):105365. doi: 10.1016/j.jbc.2023.105365
24. Godbole S, Bowler RP. Metabolome Features of COPD: A Scoping Review. Metabolites. 2022;12(7):621. doi: 10.3390/metabo12070621
25. Ran N, Pang Z, Gu Y, Pan H, Zuo X, Guan X, et al. An Updated Overview of Metabolomic Profile Changes in Chronic Obstructive Pulmonary Disease. Metabolites. 2019;9(6):111. doi: 10.3390/metabo9060111
26. Gillenwater LA, Pratte KA, Hobbs BD, Cho MH, Zhuang Y, Halper-Stromberg E, et al. Plasma Metabolomic Signatures of Chronic Obstructive Pulmonary Disease and the Impact of Genetic Variants on Phenotype-Driven Modules. Netw Syst Med. 2020;3(1):159-181. doi: 10.1089/nsm.2020.0009
27. Naz S, Kolmert J, Yang M, Reinke SN, Kamleh MA, Snowden S, et al. Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD. Eur Respir J. 2017;49(6):1602322. doi: 10.1183/13993003.02322-2016
28. Zhang Y, Ma X, Wu F, Sun Y, Mou H, Liu X, et al. The relationship between genetic prediction of 486 blood metabolites and the risk of COPD: mendelian randomization study. Sci Rep. 2025;15(1):7349. doi: 10.1038/s41598-025-92216-0
29. Gillenwater LA, Helmi S, Stene E, Pratte KA, Zhuang Y, Schuyler RP, et al. Multi-omics subtyping pipeline for chronic obstructive pulmonary disease. PLoS One. 2021;16(8):e0255337. doi: 10.1371/journal.pone.0255337
30. Liang Y, Gai XY, Chang C, Zhang X, Wang J, Li TT. Metabolomic Profiling Differences among Asthma, COPD, and Healthy Subjects: A LC-MS-based Metabolomic Analysis. Biomed Environ Sci. 2019;32(9):659-672. doi: 10.3967/bes2019.085
31. Johnson RK, Brunetti T, Quinn K, Doenges K, Campbell M, Arehart C, et al. Discovering metabolite quantitative trait loci in asthma using an isolated population. J Allergy Clin Immunol. 2022;149(5):1807-1811.e16. doi: 10.1016/j.jaci.2021.11.002
Review
For citations:
Nikitina L.Y., Buikin S.V., Weber V.R., Gasanov M.Z., Avdeev S.N. Multi-omics of chronic obstructive pulmonary disease: from genetic and metabolomic disorders to personalized medicine. South Russian Journal of Therapeutic Practice. 2025;6(4):28-42. (In Russ.) https://doi.org/10.21886/2712-8156-2025-6-4-28-42
Views:
321
JATS XML
Email this article 